Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Alzheimer's Disease

Treatments: Drug: Rosiglitazone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00428090

105640

Details and patient eligibility

About

Rosiglitazone (RSG) has been tested and is approved as a treatment for type II diabetes mellitus, a disease that occurs when the body ineffectively uses glucose. RSG XR, the investigational drug, is an extended-release form of RSG. This study tests whether RSG XR safely provides benefit to people with mild to moderate Alzheimer's disease (AD). RSG XR is a new approach to AD therapy and this study tests whether one's genes alter the effectiveness of RSG XR. Glucose is used by cells to make energy that they need to live. Changes in the ability of cells to use of glucose can lead to diseases like diabetes. Glucose levels may be lower in the brains of AD patients, and their brain cells may also use glucose less well than in unaffected people. The proper function of brain cells may be critical to memory and thought. If brain cells use glucose poorly, this might impact AD. Drugs that help brain cells properly use glucose may help a person maintain normal memory and thinking. Data suggesting that RSG may help AD patients was first seen in a small study at the Univ. of Washington and then from a larger international GSK study. In the first study, those receiving RSG once daily for 6 months scored better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that benefited most from therapy with RSG XR had a specific genetic pattern. They lacked the gene that caused them to produce apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene from one parent. Subjects with one copy of the APOE e4 gene remained fairly stable while those with two copies of APOE e4 continued to worsen during the 6-month treatment. This study will directly test the effect of RSG XR on people who either have or lack the APOE e4 gene.

Full description

A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer's disease. (REFLECT-1)

Enrollment: 862 patients

Sex: All

Ages: 50 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of probable Alzheimer's Disease (AD).
• MMSE score 10 to 23
• Has not taken an approved AD therapy in last 30 days.
• No previous hypersensitivity/intolerance to AChEIs
• Have a regular caregiver.

Exclusion criteria

• Diagnosis of vascular dementia.
• Type I or secondary diabetes mellitus.
• Type II diabetes mellitus treated with insulin, sulfonylurea or glipizide.
• History or evidence of congestive heart failure, clinically significant peripheral edema or anemia.
• History of significant psychiatric illness, major depressive disorder or current depression needing initiation of treatment.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

862 participants in 2 patient groups

Rosiglitazone

Experimental group

Description:

XR (extended release) oral tablets

Treatment:

Drug: Rosiglitazone

Placebo

Other group

Description:

Placebo (Double-Dummy to Match)

Treatment:

Drug: Rosiglitazone